Prazepam

Prazepam

SCHEMBL78272

O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ

The experimentally established mechanism targets of Prazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP known ✓ O00591 1/20 0.64
GABRD known ✓ O14764 1/20 0.64
GABRA1 known ✓ P14867 1/20 0.64
GABRB1 known ✓ P18505 1/20 0.64
GABRG2 known ✓ P18507 1/20 0.64
GABRB3 known ✓ P28472 1/20 0.64
GABRA5 known ✓ P31644 1/20 0.64
GABRA3 known ✓ P34903 1/20 0.64
GABRA2 known ✓ P47869 1/20 0.64
GABRB2 known ✓ P47870 1/20 0.64
GABRA4 known ✓ P48169 1/20 0.64
GABRE known ✓ P78334 1/20 0.64
GABRA6 known ✓ Q16445 1/20 0.64
GABRG1 known ✓ Q8N1C3 1/20 0.64
GABRG3 known ✓ Q99928 1/20 0.64
GABRQ known ✓ Q9UN88 1/20 0.64
OPRK1 P41145 4/20 0.69
NR1I2 O75469 1/20 0.69
ADORA3 P0DMS8 1/20 0.69
OPRM1 P35372 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Prazepam SCHEMBL29565880 1.00 OPRK1 (0.69) OPRK1NR1I2ADORA3OPRM1TP53
Prazepam SCHEMBL7617057 0.92 OPRK1 (0.60) OPRK1NR1I2ADORA3OPRM1TP53
Prazepam SCHEMBL4282434 0.89 TP53 (0.60) OPRK1NR1I2ADORA3OPRM1TP53
Prazepam SCHEMBL312369 0.88 OPRK1 (0.72) OPRK1NR1I2ADORA3OPRM1TP53
SCHEMBL11770839 0.88 TP53 (0.69) OPRK1NR1I2ADORA3OPRM1TP53
SCHEMBL13352310 0.86 TP53 (0.58) OPRK1NR1I2ADORA3OPRM1TP53
Prazepam SCHEMBL18321926 0.86 OPRK1 (0.54) OPRK1NR1I2ADORA3OPRM1TP53
Prazepam SCHEMBL7537961 0.86 LMNA (0.64) OPRK1NR1I2ADORA3OPRM1TP53
Flutoprazepam SCHEMBL124578 0.86 OPRK1 (0.67) OPRK1NR1I2ADORA3OPRM1TP53
Flutoprazepam SCHEMBL29440278 0.86 OPRK1 (0.67) OPRK1NR1I2ADORA3OPRM1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 12583 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092932-A1 METHODS AND COMPOSITIONS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER THE JOHNSON CENTER FOR CHILD HEALTH AND DEV (US) 2026-04-02 US claimed
US-20260076953-A1 METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2026-03-19 US claimed
US-20260027337-A1 TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS MORNINGSIDE VENTURE INVESTMENTS LTD (MC) 2026-01-29 US claimed
US-12515030-B2 Transdermal drug delivery devices and methods MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) 2026-01-06 US claimed
US-20250375421-A1 METHODS OF USING DMT SHULMAN WILLIAM (US) 2025-12-11 US claimed
EP-4622640-A1 COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF Brightseed, Inc. (US) 2025-10-01 EP claimed
US-20250281451-A1 COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF BRIGHTSEED, INC. 2025-09-11 US claimed
US-12396981-B2 Methods of using DMT SHULMAN WILLIAM (US) 2025-08-26 US claimed
WO-2025126159-A1 A METHOD FOR TREATING A NEUROLOGICAL DISEASE IN A RECREATIONAL DRUG USER TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-06-19 WO claimed
US-20250179064-A1 BENZOQUINOLONE INHIBITORS OF VMAT2 AUSPEX PHARMACEUTICALS LLC 2025-06-05 US claimed
EP-0216555-A2 Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections BTG INTERNATIONAL LIMITED (GB) 1987-04-01 EP claimed
EP-0098113-B1 A COMBINATION OF BETA-ADRENOCEPTOR ANTAGONISTS AND ANXIOLYTIC AGENTS AYERST, MCKENNA AND HARRISON INC. (CA) 1986-09-03 EP claimed
US-4595684-A Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof CIBA-GEIGY CORPORATION (US) 1986-06-17 US claimed
US-4557934-A ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE THE PROCTER & GAMBLE COMPANY (US) 1985-12-10 US claimed
EP-0150721-A2 Drug Firma Paliz, Ziegler (CH) 1985-08-07 EP claimed
EP-0098113-A1 A combination of beta-adrenoceptor antagonists and anxiolytic agents AYERST, MCKENNA AND HARRISON INC. (CA) 1984-01-11 EP claimed
US-4316897-A TRANQUILIZERS HOFFMANN-LA ROCHE INC. (US) 1982-02-23 US claimed
EP-0025546-A2 Therapeutical use of tranquillizing benzodiazepine derivatives and mixtures containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-03-25 EP claimed
US-4028467-A Analgesic compositions comprising levo-propoxyphene and benzo diazepine and process BERGER FRANK M 1977-06-07 US claimed
US-4028466-A Analgesic compositions comprising dextro-propoxyphene and benzodiazepine and process BERGER FRANK M 1977-06-07 US claimed